Prospective study of photorefractive keratectomy for myopia using the VISX StarS2 excimer laser system

To evaluate the safety, efficacy, and predictability of excimer laser photorefractive keratectomy (PRK) for compound myopic astigmatism using the VISX StarS2 excimer laser system with international version 3.1 software.

We report a prospective consecutive study of myopic excimer laser PRK, performed in a multi-surgeon environment with 200 eyes of 117 patients, to correct naturally occurring compound myopic astigmatism of between -0.50 to -5.90 D manifest refractive sphere and up to -3.50 D manifest refractive astigmatism. Patients were assessed prior to surgery and at 1, 3, 6, and 12 months after treatment.

One hundred and ninety-eight of 200 treatments (99%) were reviewed 1 year after surgery; 193 of 198 eyes (97%) achieved 20/40 or better uncorrected visual acuity and 163 of 198 eyes (82%) achieved 20/20 or better. One eye lost two lines of Snellen visual acuity assessed at 12 months but recovered acuity when assessed at 18 months. Mean spherical equivalent corneal plane power was reduced from -3.50 to +0.90 D 1 month after treatment and 0 D at 12 months (SD 0.67 D). Three eyes of three patients underwent further treatment, two with LASIK and one with PRK for residual refractive error. Refractive astigmatism of >1.00 D was reduced from a mean -1.70 to -0.70 D at 1 year after treatment. Vector magnitude was 79% of that intended and mean vector axis error (absolute) was 8.5 degrees. No eye had a severe haze response. Pelli-Robson contrast acuity was significantly reduced after treatment from a mean 1.72 D preoperatively to 1.63 D at 12 months (P<.01).

PRK for myopia using the VISX StarS2 excimer laser system was effective in the treatment of low myopic astigmatism, although there was a significant reduction in Pelli-Robson contrast sensitivity.